Loading
A phase 2 trial of Disitamab vedotin, Pertuzumab and Toripalimab in HER2-positive breast cancer, run by RemeGen Co., Ltd., now recruiting.
DV in Combination With Pertuzumab With or Without Toripalimab Neoadjuvant Therapy With HER2-positive Breast Cancer is a phase 2 interventional study registered as NCT06178159 by RemeGen Co., Ltd., with 40 participants planned, started 2023-11-28 and due to reach its primary completion in 2026-06. Interventions recorded: Disitamab Vedotin Injection, Pertuzumab Injection and Toripalimab.
Shares RemeGen, Disitamab vedotin, Toripalimab, HER2-positive breast cancer and the tag pipeline.
Shares RemeGen, Disitamab vedotin, Toripalimab, HER2-positive breast cancer and the tag pipeline.
Shares RemeGen, Disitamab vedotin, Toripalimab, HER2-positive breast cancer and the tag pipeline.
Shares RemeGen, Disitamab vedotin, Toripalimab, Antibody-drug conjugate (ADC) and the tag pipeline.
Shares RemeGen, Disitamab vedotin, HER2-positive breast cancer, Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Early HER2-positive breast cancer, Pertuzumab, HER2-positive breast cancer, Monoclonal antibodies and the tag pipeline.
Shares RemeGen, Disitamab vedotin, Monoclonal antibodies, Antibody-drug conjugate (ADC) and the tag pipeline.
Shares RemeGen, Disitamab vedotin, Antibody-drug conjugate (ADC) and the tag pipeline.